Related references
Note: Only part of the references are listed.Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2-Overexpressing Locally Advanced Breast Cancers
Bhuvanesh Dave et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Tyrosine Phosphorylation Profiling Reveals the Signaling Network Characteristics of Basal Breast Cancer Cells
Falko Hochgraefe et al.
CANCER RESEARCH (2010)
KEA: kinase enrichment analysis
Alexander Lachmann et al.
BIOINFORMATICS (2009)
Src inhibitors in early breast cancer: a methodology, feasibility and variability study
R. J. Jones et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Teemu T. Junttila et al.
CANCER CELL (2009)
c-Src Associates with ErbB2 through an Interaction between Catalytic Domains and Confers Enhanced Transforming Potential
Richard Marcotte et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
A phase I trial of the combination of dasatinib and lapatinib
Charles Erlichman et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530
Tim P. Green et al.
MOLECULAR ONCOLOGY (2009)
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
Violeta Serra et al.
CANCER RESEARCH (2008)
A central role for HER3 in HER2-amplified breast cancer:: implications for targeted therapy
Si Tuen Lee-Hoeflich et al.
CANCER RESEARCH (2008)
Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
Pieter J. A. Eichhorn et al.
CANCER RESEARCH (2008)
Global impact of oncogenic Src on a phosphotyrosine proteome
Weifeng Luo et al.
JOURNAL OF PROTEOME RESEARCH (2008)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/triple-negative'' breast cancer cell lines growing in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Targeting the function of the HER2 oncogene in human cancer therapeutics
M. M. Moasser
ONCOGENE (2007)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
Proteomic parsimony through bipartite graph analysis improves accuracy and transparency
Bing Zhang et al.
JOURNAL OF PROTEOME RESEARCH (2007)
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB Ligands and remain dependent on the ErbB receptor network
Christoph A. Ritter et al.
CLINICAL CANCER RESEARCH (2007)
c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function
R. C. Ishizawar et al.
ONCOGENE (2007)
Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: Rationale for patient selection
Fei Huang et al.
CANCER RESEARCH (2007)
MyriMatch: Highly accurate tandem mass spectral peptide identification by multivariate hypergeometric analysis
David L. Tabb et al.
JOURNAL OF PROTEOME RESEARCH (2007)
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Natalia V. Sergina et al.
NATURE (2007)
Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity
Wanping Xu et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Detecting differential and correlated protein expression in label-free shotgun proteomics
Bing Zhang et al.
JOURNAL OF PROTEOME RESEARCH (2006)
N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor
Laurent F. Hennequin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells
Raoul Tibes et al.
MOLECULAR CANCER THERAPEUTICS (2006)
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors
Shizhen Emily Wang et al.
CANCER CELL (2006)
Phosphoproteomic analysis of Her2/neu signaling and inhibition
Ron Bose et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
GE Konecny et al.
CANCER RESEARCH (2006)
The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation
H Kim et al.
ONCOGENE (2005)
Comparison of label-free methods for quantifying human proteins by shotgun proteomics
WM Old et al.
MOLECULAR & CELLULAR PROTEOMICS (2005)
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
HA Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Src kinase regulation by phosphorylation and dephosphorylation
R Roskoski
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
ErbB2 promotes Src synthesis and stability: Novel mechanisms of Src activation that confer breast cancer metastasis
M Tan et al.
CANCER RESEARCH (2005)
Immunoaffinity profiling of tyrosine phosphorylation in cancer cells
J Rush et al.
NATURE BIOTECHNOLOGY (2005)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata et al.
CANCER CELL (2004)
Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
LJ Lombardo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215
RK Vadlamudi et al.
FEBS LETTERS (2003)
Src family kinases and HER2 interactions in human breast cancer cell growth and survival
AP Belsches-Jablonski et al.
ONCOGENE (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Share Paper
